DDAH1 Antibody

說明書

中文名稱：

DDAH1兔多克隆抗體
貨號：

CSB-PA252663
規格：

￥1100
圖片：
The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using CSB-PA252663(DDAH1 Antibody) at dilution 1/55, on the right is treated with synthetic peptide. (Original magnification: ×200)

The image on the left is immunohistochemistry of paraffin-embedded Human brain tissue using CSB-PA252663(DDAH1 Antibody) at dilution 1/55, on the right is treated with synthetic peptide. (Original magnification: ×200)
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

Uniprot No.：

O94760
基因名：

DDAH1
別名：

DDAH antibody; DDAH I antibody; DDAH-1 antibody; DDAH1 antibody; DDAH1_HUMAN antibody; DDAHI antibody; Dimethylargininase 1 antibody; Dimethylargininase-1 antibody; Dimethylarginine dimethylaminohydrolase 1 antibody; N(G) antibody; N(G)-dimethylarginine dimethylaminohydrolase 1 antibody; NG NG dimethylarginine dimethylaminohydrolase antibody
宿主：

Rabbit
反應種屬：

Human,Mouse,Rat
免疫原：

Synthetic peptide of Human DDAH1
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
抗體亞型：

IgG
純化方式：

Antigen affinity purification
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
產品提供形式：

Liquid
應用范圍：

ELISA,IHC

推薦稀釋比：

Application	Recommended Dilution
ELISA	1:1000-1:5000
IHC	1:50-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Hydrolyzes N(G),N(G)-dimethyl-L-arginine (ADMA) and N(G)-monomethyl-L-arginine (MMA) which act as inhibitors of NOS. Has therefore a role in the regulation of nitric oxide generation.
基因功能參考文獻：
1. MiR-21-mediated DDAH1/ADMA/NO signal pathway. PMID: 29682517
2. DDAH-1 expression is associated with promotion of angiogenesis stimulating factor VEGF. PMID: 28741166
3. These findings suggest that DDAH1 functions as a tumor suppressor in gastric cancer (GC) and may be exploited as a diagnostic and prognostic biomarker for GC. PMID: 28580735
4. Data demonstrate that DDAH1 deficiency promotes the epithelial to mesenchymal transition in renal proximal tubular epithelial cells and causes fibrosis, and oxidative stress in aging and diabetic kidneys. The study provides the first direct evidence that the DDAH1 has a marked effect on kidney fibrosis and oxidative stress induced by aging or diabetes. PMID: 28594240
5. Results confirmed DDAH1 3'-UTR as a target for miR-21, and endogenous miR-21 showed increased inhibitory effect on DDAH1-V3 transcript. PMID: 27663503
6. Inflammatory factors expressed in response to myocardial ischemia contributed to up-regulation of DDAH1. PMID: 28145161
7. DDAH1 plays dual roles in a particular matter-induced cell death in alveolar epithelial cells. PMID: 26996393
8. rs3087894 in DDAH1 was significantly associated with hypertension and showed conflicting results in different ethnic groups. This is therefore a candidate for further studies with the aim of helping to ascertain the mechanisms of hypertension in different populations. PMID: 26786611
9. wild-type rs480414 was 92% sensitive and 53% specific for pulmonary hypertension in bronchopulmonary dysplasia PMID: 26663142
10. results suggest that miR-21 may regulate renal fibrosis by the Wnt pathway via directly targeting DDAH1 PMID: 26455824
11. The most significant associations were detected for PECAM1*V/V + DDAH1*C (OR = 4.17 CI 1.56-11.15 Pperm = 0.005) PMID: 26662939
12. FoxO1 regulates asymmetric dimethylarginine via downregulation of dimethylaminohydrolase 1 in HUVECs and subjects with carotid atherosclerosis. PMID: 26226438
13. Genebased analyses revealed associations of the DDAH1 gene with longitudinal Blood Pressure phenotypes, associations with essential hypertension, Blood Pressure salt sensitivity, preeclampsia, or preclinical stages of atherosclerosis. PMID: 25424718
14. DDAH1 deficiency attenuates endothelial cell cycle progression and angiogenesis. PMID: 24260221
15. the advanced glycation end products-receptor for advanced glycation end products-mediated reactive oxygen species generation could be involved in endothelial dysfunction in diabetic end-stage renal disease patients PMID: 23766377
16. DDAH1 genotypes were closely related to asymmetric dimethylarginine levels, but not to measures of endothelium-dependent vasodilation in an elderly population. PMID: 23892448
17. Only the DDAH1-V1 transcript is responsible for ADMA metabolism, and transcript specific primers are recommended to determine DDAH1 mRNA expression. PMID: 23864585
18. Elevated asymmetric dimethylaginine is not a part of the proatherogenic risk profile in the young adult offspring of patients with premature Coronary artery disease. PMID: 23022711
19. A significant decrease in asymmetric dimethylarginine levels was found in ex-extremely low birth weight young adults compared to term birth weight young adults. PMID: 21420186
20. Data suggest that estradiol alone has no effect on DDAH/asymmetric dimethylarginine/nitric oxide pathway in arterial endothelium, but rather counters oxidized LDL; estradiol restores DDAH activity and prevents loss of eNOS (nitric oxide synthase 3). PMID: 22982060
21. DDAH1 gene DNA methylation is impoetant in the pathogenesis of idiopathic pulmonary fibrosis. PMID: 22700861
22. Genetic polymorphisms in DDAH genes influence serum ADMA levels in individuals with T1 diabetes mellitus. PMID: 22521321
23. High DDAH1 is associated with pediatric diffuse intrinsic pontine glioma. PMID: 22492959
24. Non-diabetic hypertensive subjects with a hypertensive response to exercise compared to those with normal response were characterized by augmented asymmetric dimethylarginine and osteoprotegerin levels. PMID: 21975354
25. did not find evidence for association with pre-eclampsia PMID: 21174581
26. In acute congestive heart failure acute renal impairment function and the modulation of metabolism and extracellular transport by the DDAH-1/CAT-1 system determine high ADMA and SDMA levels after therapy for acute congestive heart failure. PMID: 21722652
27. Data show that DDAH inhibition reduces fibroblast-induced collagen deposition in an ADMA-independent manner and reduces abnormal epithelial proliferation in an ADMA-dependent manner. PMID: 21677199
28. HDL significantly increased the attenuated endothelial cell NO production induced by ox-LDL, which was attributed to its effect on DDAH/ADMA pathway PMID: 21264497
29. Indicate that DDAH1 is required for metabolizing asymmetrical dimethylarginine and N(omega)-monomethyl-L-arginine. PMID: 21493890
30. Results provide evidence that SNP rs1241321 in DDAH1 is associated with type 2 diabetes and its long-term outcome. PMID: 21303562
31. DDAH1 exerts a unique role in activating Akt that affects endothelial function independently of degrading endogenous nitirc oxide synthase inhibitors. PMID: 21212404
32. Recent studies in this review suggest that DDAH may regulate endothelial nitric oxide activity and endothelial function through both asymmetric dimethylarginine-dependent and -independent mechanisms. PMID: 19682581
33. Expression of hDDAH1 messenger RNA is found in all organs of DDAH1 transgenic mice investigated, whereas human DDAH1 is absent in wild-type littermates. PMID: 19666120
34. Circulating methylarginine levels and the decline in renal function in patients with chronic kidney disease are modulated by DDAH1 polymorphisms. PMID: 20010544
35. Results suggest that the DDAH1 loss-of-function polymorphism is associated with both increased risk of thrombosis stroke and coronary artery disease in the Chinese Han population. PMID: 20167924
36. Recombinant human DDAH1 overexpression protects transgenic mice from adverse structural and functional changes in cerebral arterioles in hyperhomocysteinemia but not from accelerated carotid artery thrombosis induced by the HM/LF diet. PMID: 20019334
37. hydrolyzes methylated inhibitors of nitric oxide synthase is present in circulating human red blood cells PMID: 11811522
38. The first evidence of the importance of DDAH1 polymorphisms in pre-eclampsia susceptibility was provided. PMID: 15501905
39. By increasing the synthesis of the proangiogenic factor nitric oxide, DDAH promotes postnatal angiogenesis and arteriogenesis. PMID: 15781754
40. DDAH-1 and DDAH-2 messenger RNA and protein were demonstrated in first trimester placental tissue, primary extravillous trophoblasts and extravillous trophoblast-derived cell lines. PMID: 16920729
41. it is concluded that L-arginine regulates asymmetric dimethylarginine (ADMA) metabolism dose-dependently by competing for DDAH thus maintaining the metabolic balance of L-arginine and ADMA, and endothelial NO homeostasis PMID: 17075694
42. DDAH-1 activity leads to accumulation of asymmetric dimethylarginine and reduction in nitric oxide signaling. PMID: 17273169
43. Demonstrate a critical role for DDAH-1 and endogenous methylarginines in the pathogenesis of endothelial dysfunction. PMID: 17881609
44. human dimethylarginine dimethylaminohydrolase-1 is inhibited by S-nitroso-L-homocysteine and hydrogen peroxide PMID: 17895252
45. maintenance of normoglycemia and not glycemia-independent actions of insulin maintained dimethylarginine tissue levels by preserving physiological DDAH activity. PMID: 18292189
顯示更多

收起更多
蛋白家族：

DDAH family
組織特異性：

Detected in brain, liver, kidney and pancreas, and at low levels in skeletal muscle.
數據庫鏈接：

HGNC: 2715

OMIM: 604743

KEGG: hsa:23576

STRING: 9606.ENSP00000284031

UniGene: Hs.713411

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human